Guardant360 (Guardant Health Inc.)
HAYES, Inc
Record ID 32017000084
English
Authors' objectives:
Guardant360 is a liquid biopsy noninvasive blood screen used to identify actionable alterations across all solid tumor sites and provide a report, which identifies Food and Drug Administration (FDA)-approved treatments and clinical trials to help guide treatment decisions. The focus of this review is to assess the evidence that supports the use of Guardant360 as a decision-making tool, which identifies potentially actionable genetic mutations to help guide treatment options.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
The report may be purchased from:
http://www.hayesinc.com/hayes/crd/?crd=50466
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Biopsy
- Mutation
- Decision Making
- Neoplasms
- United States Food and Drug Administration
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.